The short answer
Two receptors do most of the work: CB1 and CB2. Both are G-protein coupled receptors, both sit inside the endocannabinoid system, and both respond to THC in ways researchers can measure. Beyond those two, the picture gets messier. GPR55 and GPR18 are often called cannabinoid receptors even though they look nothing like CB1. TRPV1, PPARs, and 5-HT1A respond to cannabinoids too, but most pharmacologists file them as cannabinoid-responsive rather than true cannabinoid receptors.
So the count breaks down like this: two canonical receptors, two or three strong candidates, and a handful of indirect targets that still shape what you feel.
what makes cb2 receptors an anti inflammatory target
CB1: the one behind the high
CB1 lives mainly in the central nervous system. Density is highest in the cortex, hippocampus, cerebellum, and basal ganglia, which is why THC tugs on memory, coordination, mood, and time perception at the same time. It's a Gi/o-coupled receptor, so activation tends to suppress cAMP and dampen neurotransmitter release.
Do CBD and THC Act on Different Receptors?
It isn't brain-only. CB1 shows up in the gut, liver, and peripheral nerves. That helps explain why cannabis can shift appetite and nausea before any euphoria lands.
how does thc bind to cb1 receptors
THC is a partial agonist at CB1. CBD is a weak negative allosteric modulator, meaning it doesn't activate the receptor directly but can change how THC binds and signals. That distinction explains a lot of the "CBD takes the edge off THC" talk.
CB2: the immune system's receptor
CB2 is expressed on immune cells: B cells, T cells, macrophages, microglia. It's also in gut and peripheral tissue. Selective CB2 agonists get studied for inflammation and pain without psychoactivity, though human trials have been mixed and a few candidates stalled out.
Microglia in the brain do carry CB2, often upregulated after injury. That makes CB2 a research focus for neuroinflammation rather than mood or perception.
The "third receptor" candidates: GPR55 and GPR18
Neither looks much like CB1 or CB2, but both bind cannabinoids.
GPR55 is activated by lysophosphatidylinositol, anandamide, THC, and CBD, depending on the assay. It signals through G12/13 and Rho, a different pathway than CB1 uses. Some papers call it CB3. Most journals don't, because the pharmacology shifts from lab to lab.
GPR18 responds to N-arachidonoyl glycine, THC, and abnormal cannabidiol. It's been tied to immune cell migration and, in some models, to retinal and cardiovascular effects. The evidence is real but thin next to CB1.
When I read these papers, I look for one thing: does the effect survive a CB1 or CB2 antagonist? If it doesn't, the receptor claim is usually doing more work than the data.
Targets that respond without being cannabinoid receptors
- TRPV1: the capsaicin receptor, also activated by anandamide and CBD. It drives burning sensations and some anti-inflammatory signaling.
- PPAR alpha and PPAR gamma: nuclear receptors that change gene expression. Anandamide and 2-AG act here, and CBD is a known PPAR gamma agonist.
- 5-HT1A: a serotonin receptor. CBD acts as an agonist, one proposed route for its anxiolytic effects.
- GPR119: responds to oleoylethanolamide and appears in metabolic and appetite research.
Why the list keeps growing
Better tools are part of it. Cryo-EM structures and selective ligands let researchers separate real binding from assay noise. The other part is definitional. "Cannabinoid receptor" started as a functional label: a site that binds THC or endocannabinoids and changes cell signaling. Under that looser definition, the list balloons.
Most reviews still settle on CB1 and CB2 as the only confirmed receptors, with GPR55 and GPR18 as candidates. TRP channels and PPARs are parallel or downstream targets, not receptors in the classic sense.
What it means if you're just buying something
Convenience formats change the dose curve more than they change the receptor. A fast-dissolving gummy or a vape gets THC to CB1 in minutes. A standard edible can take an hour or more because of first-pass metabolism. Same receptor, very different afternoon.
If a label names a specific receptor, treat it as marketing unless a study is cited. CB2-selective claims are the most common and the most oversold, since selective CB2 agonists haven't reliably delivered in human trials.